Among the 240 breast cancer patients, there were 61 (25.4%) with luminal A, 127 (52.9%) with luminal B type, 31 (12.6%) with HER2 overexpression, and 21 (8.8%) were triple negative (TN) types. This evidence concerns the gene ERBB2 and breast cancer.